10-12 December, 2018

London, UK

Speakers

Expand/Collapse

Robert (Bob) Anderson
CSO
ImmusanT

After training as a gastroenterologist, Bob’s career over the last 20 years has focused on designing and developing a therapeutic vaccine for celiac disease. Since 2012 he has been Chief Scientific Officer at ImmusanT Inc. in Cambridge MA. The research he initiated in the UK while a post-doctoral scientist at Oxford University and continued at the Walter and Eliza Hall Institute and Royal Melbourne Hospital in Australia mapped the key immune targets in gluten that account for its toxicity.

Day Two

Wednesday, 12th December, 2018

12.00 | Clinical and Immunological Effects of Peptide-Based Epitope-Specific Immunotherapy (ESIT) In Celiac Disease

Arpita Maiti Senior
Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome
Pfizer

As Senior Director, External Science & Innovation (ES&I), Arpita is a member of the external opportunities (discovery to Proof of Concept) search and evaluation team for Inflammation & Immunology, at Pfizer.  She also leads strategy and partnering efforts in the microbiome for Pfizer.  ES&I is an externally-focused scientific team of PhDs / MDs, embedded within Pfizer research groups, that identifies late-breaking science forming the basis of innovative therapies, and drives related collaborations that deliver value to Pfizer, its partners, and patients.  Prior to Pfizer, she was Associate Director of R&D Alliance Design & Management at Vertex Pharmaceuticals.

Day One

Tuesday, 11th December, 2018

12.00 | Accessing Innovation in Antigen-Specific Immune Tolerance – A Big Pharma View

08.50 | Chair’s Opening Remarks

Keith Martin
CEO
Apitope

Keith Martin is a successful leader, inventor and entrepreneur in both pharmaceutical and biotech companies. Keith has extensive experience in executive (CEO) and non-executive directorships, senior positions in R&D and corporate & business development in pharma and has raised more than €50 M in equity and non-dilutive funding. He has also developed multiple products from bench through clinical trials, captured value through significant licensing deals and advised on venture investment. As the CEO of Apitope, focused on researching & developing antigen specific immunotherapeutic peptides for autoimmune diseases, the company has closed financing of €10 M (Series A in Oct 08) and €15 M (Series B in Sept 15) and a €150 M+ licensing deal and completed of 4 successful Phase I/II clinical trials in MS and Graves’ disease patients with initial proof of principle; CTA approved for trial in haemophillia A.

Day Two

Wednesday, 12th December, 2018

11.30 | Antigen Specific Immunotherapy with Apitopes®: From Concept to Clinic

10.30 | Panel Discussion: Improving Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies

Timm Jessen
CEO
Topas Therapeutics

Head of Biotechnology/Germany at Hoechst Marion Roussell (1991-1997), CSO of Evotec (1997-2004), Co-Founder of Scienamics, 2cureX, Bionamics and Topas Therapeutics.

Day Two

Wednesday, 12th December, 2018

10.30 | Panel Discussion: Improving Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies

09.30 | Liver Based Immune Tolerance Induction

Pierre Vandepapeliere
CEO & CMO
ImCyse

Pierre Vandepapelière, M.D.,PhD is CEO and CMO of Imcyse since February 2015. He has transformed an academic research group into a rapidly growing Biotech company. Imcyse is a biotech company developing a technology platform offering multiples opportunities such as active specific immunotherapeutics (Imotopes) to treat and to prevent auto immune diseases or allergic diseases or to down regulation of immune response against immunogenic drugs. Before joining Imcyse he was head of early clinical research at GlaxoSmithKline Biologicals. He has extended experience in development of vaccines worldwide, specifically therapeutic vaccines for chronic infectious diseases,  and in the evaluation and use of adjuvants in vaccines.  Pierre also spent 7 years as head of development at Neovacs, Paris, and as consultant he implemented phase IIb programs in other Biotech companies. He graduated in Medicine at the Catholic University of Louvain, in Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium and has a PhD from the University of Gent.

Day Two

Wednesday, 12th December, 2018

14.30 | Imotopes Induce Cytolytic CD4 T Cells as a Novel Strategy to Treat Autoimmune Diseases

Charlotte Fribert
CEO
Toleranzi AB

Charlotte Fribert, CEO of Toleranzia, studied medicine at the Karolinska Institute and at the Pierre and Marie Curie University of Sorbonne in Paris, where she also obtained a PhD in immunology and biotechnology. Before Fribert began working at Toleranzia she worked as Project Director in drug development at AstraZeneca in Mölndal. Prior to this, she founded, developed and led Epixis SA, a vaccine development company based in Paris, which was successfully sold to VBI Vaccines Inc. in the US. Fribert has thus considerable experience both in Toleranzia’s therapy area and in the effective development of small life science companies.

Day One

Tuesday, 11th December, 2018

14.30 | TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis

Mark Peakman
Professor of Clinical Immunology- Faculty of Life Sciences & Medicine
King’s College London

Mr. Mark Peakman, MSc, Ph.D. serves as a Member of Clinic Advisory Board at SEKRIS Biomedical, Inc. Mr. Peakman serves as Member of Type 1 Diabetes Scientific Advisory Board at Caladrius Biosciences, Inc. Mr. Peakman held a senior clinical research fellowship at the University of Pittsburgh. He subsequently returned to the UK and oversees a research group at King’s College London in the Department of Immunobiology. He trained in medicine at University College London and pursued postgraduate training in clinical immunology. He received his PhD based on studies of the immune system in Type 1 diabetes.

Day One

Tuesday, 11th December, 2018

13.00 | Measuring and Limiting Antigen-Specific Immune Tolerance in Type 1 Diabetes

Lawrence Steinman
Professor at Stanford University; Chairman of the Board
Tolerion

Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on what provokes relapses and remissions in multiple sclerosis (MS) and in neuromyelitis optica (NMO) and the quest for antigen specific therapy. He is developing a small molecule therapeutic in trials for Huntington’s Disease. Steinman identified guardian molecules in brain that have protective properties in a number of inflammatory conditions. These protective molecules activate regulatory B cells.

Day Two

Wednesday, 12th December, 2018

12.30 | Engineered DNA Plasmid for Tolerance in Type 1 Diabetes, NMO and Gene Therapy

Ethan Shevach
Senior Investigator- Laboratory of Immune System Biology
NIAID/NIH

Dr. Shevach received his A.B. and M.D. degrees from Boston University. He is presently Chief, Cellular Immunology Section, Laboratory of Immune System biology.  Dr. Shevach is the author of over 450 papers in the field of Immunology and his research interests over the years have included antigen presentation and processing, T lymphocyte activation, pathogenesis of autoimmunity, and most recently the role of regulatory T cells in immune responses. He served as Editor-in-Chief of the Journal of Immunology from 1987 to 1992 and as Editor-in-Chief of Cellular Immunology from 1996 to 2007. He is a member of the editorial boards of several journals including Immunity, Journal of Experimental Medicine, and Human Immunology.

Workshop A

Monday, 10th December, 2018

10.00 | Translation from Animal to Human Studies: Role of T Regulatory Cells in the Induction/Maintenance of Tolerance

David Wraith
Institute Director of Immunology & Immunotherapy and Professor of Immunology
University of Birmingham

David Wraith is Professor of Immunology, Director of the Institute of Immunology and Immunotherapy at the University of Birmingham and CSO of Apitope NV, a company that designs and develops peptides for antigen-specific immunotherapy of allergic and autoimmune diseases. David began his career at NIMR, London, working on the immune response to viruses. He received MRC funding to study autoimmunity at Stanford University. This led to him establishing a Wellcome Trust funded research laboratory at the University of Cambridge and, between 1995 and 2016, he held the Chair in Experimental Pathology in Bristol. His research group is principally supported by the Wellcome Trust, MRC, EU-Innovative Medicines Initiative, Diabetes UK, Helmsley Trust and the Children’s Liver Disease Foundation.

Day One

Tuesday, 11th December, 2018

09.00 | Antigen-Specific Immunotherapy of Autoimmune Diseases

Tim Schmidt
VP Chief Translational Research Officer
TxCell

Summary: Experienced Professional in the Translational Research and Early Clinical Development space with a demonstrated history of successfully progressing new therapeutic entities from the pre-clinical stage into Ph1 and Ph2 clinical trials in the pharmaceuticals industry setting, spanning the Immuno-Inflammation, Autoimmunity and Fibrosis therapy areas. He is currently the VP Chief Translational Research Officer at TxCell, Valbonne, Prior to that he was the Director Clinical Strategy at UCB Celltech, Slough, UK (2015-2017), Group Leader/Translational Sciences Manager at GlaxoSmithKline, Stevenage, UK (2013-2015) and R&D Manager - Immuno-Inflammation Therapy Area- Experimental Medicine Unit at GlaxoSmithKline, Stevenage, UK (2011-2013).

Day Two

Wednesday, 12th December, 2018

09.00 | Next Generation Immuno-Therapy for Transplant Rejection and Auto- Immunity: The CAR Treg Foray into The Clinic

Poul Sørensen
CSO
Allero Therapeutics

Poul Sørensen is CSO and co-founder at Allero Therapeutics, a biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders based on a novel concept for oromucosal antigen-specific tolerance induction. Prior to Allero, Poul Sørensen has more than 20 years of international research leadership experience in immunotherapy from Pharmacia, Micromet, LEO Pharma, ALK-Abello and Stallergenes and has been responsible for the discovery and development of multiple concepts and compounds in cancer, inflammation and immune mediated disorders.Poul Sørensen holds a PhD in biochemistry and molecular biology from University of Copenhagen, Denmark and is Honorary Professor of Biomedicine at Aarhus University, Denmark.

Day One

Tuesday, 11th December, 2018

12.30 | Translating the Learnings from Allergen Immunotherapy for Inducing Long Term Antigen-Specific Tolerance

José Carballido
Executive Director of Institutes Biomedical Research
Novartis

José M. Carballido is an Executive Director at the Novartis Institutes for Biomedical Research (NIBR) in Basel (CH). In 1997, José joined the Novartis Research Institute in Vienna (AT), where he held positions of increasing importance until he became the Head (Executive Director) of the Fully Integrated Program of Psoriasis. In 2008, he was appointed to his current position at the Autoimmunity, Transplantation and Inflammation Disease Area of NIBR, in Basel. José has a strong background in basic and clinical immunology, particularly in the areas of Allergy, Dermatology, Transplantation and Autoimmunity. José serves as ad-hoc reviewer for various scientific journals and private or governmental funds and he is an active member of several academic societies.

Day One

Tuesday, 11th December, 2018

10.00 | Leveraging Antigen-Specific Regulatory T Cell Responses to Defeat Type 1 Diabetes

John Isaacs
Professor of Clinical Rheumatology
Newcastle University

John Isaacs is Professor of Clinical Rheumatology at Newcastle University and a consultant rheumatologist at the Freeman Hospital, Newcastle-upon-Tyne, UK. Over the past 25 years, his work has focused on the potential of novel immunotherapies to treat rheumatoid arthritis (RA), ranging from target identification to early- and late-stage clinical trials. He has performed several pioneering experimental medicine studies in patients with inflammatory disease, challenging existing dogma and informing the design of subsequent generations of therapeutic agents. In 1992 he was the first to demonstrate immunogenicity of a humanised therapeutic antibody, CAMPATH-1H (Lancet). Professor Isaacs directs Newcastle University’s Institute for Cellular Medicine (the largest Institute in the Medical Faculty), and runs a research group focussed on therapeutic tolerance induction.

Day Two

Wednesday, 12th December, 2018

10.30 | Panel Discussion: Improving Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies

10.00 | Industry-Academia Collaborations to Identify Novel Biomarkers

Kei Kishimoto
CSO
Selecta Biosciences Inc.

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology.  Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease.  Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim.  Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Day Two

Wednesday, 12th December, 2018

15.00 | Pre-Clinical and Clinical Development of ImmTOR Technology

Pieter Rottiers
CEO
ActoBio Therapeutics

Pieter Rottiers, PhD, is CEO of ActoBio Therapeutics, a wholly owned subsidiary of Intrexon Corporation and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents. Dr. Rottiers is an entrepreneurial leader with over 15 years’ experience in drug discovery and development using the ActoBiotics platform, including over 13 years leadership and managerial experience in biopharmaceutical setting. Prior to Intrexon, Dr. Rottiers held several R&D and executive management functions at ActoGeniX, a company acquired by Intrexon beginning of 2015, where he was part of the founding team and progressed 3 ActoBiotics products from discovery research into clinical trials

Day Two

Wednesday, 12th December, 2018

14.00 | Actobiotics® - A New Class of Microbe-Based Biopharmaceuticals

10.30 | Panel Discussion: Improving Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies

Stephan Kontos
Co-Founder & CSO
Anokion and Kanyos Bio

Stephan brings 12 years of drug and platform discovery experience to Anokion and leads all aspects of research, discovery, and platform development. As a co-founder, Stephan co-invented and translated the company’s tolerance technology platform from inception to evolution into an integrated R&D organization in Cambridge, US. Stephan received his B.Sc. in Chemical Engineering from the University of Texas at Austin and moved to the Swiss Federal Institute of Technology in Lausanne for his Ph.D. in Bioengineering.

Day One

Tuesday, 11th December, 2018

15.30 | Targeted Antigen Delivery to the Liver Via Synthetic Glycosylation Induces Robust Antigen-Specific Tolerance

Nicolas Poirier
CSO
OSE Immunotherapeutics

Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneers. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or complement pathways in preclinical models of transplantation, autoimmunity and chronic inflammation. He then joined the immune regulation company Effimune, where he led R&D programs for 7 years. He was appointed Chief Scientific Officer of OSE Immunotherapeutics in 2016, a biotechnology company in the field of immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and is interested in identification and development of innovative immunotherapies to establish, break, regulate or reinforce immune regulation and activation.

Day One

Tuesday, 11th December, 2018

15.00 | Anti-IL7Ra Antibody: Next Generation Anti-Cytokine Therapy

Céline Dumont
Senior Director Preclinical Pharmacology and Safety
TxCell

Experienced Professional in development of new molecules for the treatment of autoinflammatory diseases and preclinical research spanning from biologics to small molecules and translational biology. Experience: Currently she is the Director Preclinical, Pharmacology and Safety at TxCell, Valbonne, France and prior to that she was Team Leader, RIA IMED Biotech unit at AstraZeneca, Gothenburg, Sweden from 2015 to 2018.

Day One

Tuesday, 11th December, 2018

09.30 | Innovation in Restoring Immune Tolerance in Autoinflammatory Disease: Engineering CAR Regulatory T Cells

Catharien Hilkens
Reader in Immunotherapy
Newcastle University

Catharien Hilkens obtained her PhD in Immunology at the University of Amsterdam, after which she was awarded a fellowship from the European Molecular Biology Organisation (EMBO) to work at the Cancer Research UK London Research Institute. She joined Newcastle University in 2003. One of her main research lines is the development of a tolerogenic dendritic cell-based therapy for rheumatoid and inflammatory arthritis. Her other main focus is to understand the function of dendritic cells and macrophages in synovial tissue – and how these cells drive inflammatory arthritis. She is one of the founders of the European network Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (AFACTT - http://www.afactt.eu).

Workshop B

Monday, 10th December, 2018

13.30 | Standardization Considerations for Therapeutic Antigen-Specific Tolerogenic Strategies

David Klatzmann
Director - Clinical Investigation Center for Biotherapy
Sorbonne University & Pitié-Salpêtrière Hospital

As a Professor of Immunology and Director of the Biotherapy Department at the Pitié-Salpêtrière hospital and Pierre and Marie Curie medical school, my main activities have been to advance translational research in Immunology. I built-up a global organization that is one of the rare structure capable of developing biotherapies from bench to bedside. My current specific interests and research activities are in understanding development, homeostasis and function of regulatory T cells (Treg), and develop Treg-based immunotherapies.

Day One

Tuesday, 11th December, 2018

10.30 | On Treg, IL-2 and Tolerance

Michael Boyne
VP of Product Development and Analytics
Cour Pharmaceuticals

Day Two

Wednesday, 12th December, 2018

15.30 | Bringing Antigen-Specific Therapies to the Clinic